Dorcas E Beaton1,2, Lara J Maxwell3,4, Beverley J Shea3,4, George A Wells3,4, Maarten Boers3,4, Shawna Grosskleg3,4, Clifton O Bingham3,4, Philip G Conaghan3,4, Maria Antonietta D'Agostino3,4, Maarten P de Wit3,4, Laure Gossec3,4, Lyn M March3,4, Lee S Simon3,4, Jasvinder A Singh3,4, Vibeke Strand3,4, Peter Tugwell3,4. 1. From the Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Clinical Epidemiology Program, and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ontario, Canada; Department of Epidemiology and Biostatistics, and Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia. dbeaton@iwh.on.ca. 2. D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; B.J. Shea, PhD, Senior Scientist, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; L.J. Maxwell, PhD, Methodological Advisory to the Technical Advisory Group, OMERACT, University of Ottawa, and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; S. Grosskleg, BS, Secretariat, OMERACT, and University of Ottawa; C.O. Bingham III, MD, Professor of Medicine, Division of Rheumatology, Johns Hopkins University; P.G. Conaghan, MD, PhD, Director, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Deputy Director, NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Sorbonne Université, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research, and Head of Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama at Birmingham; L.S. Simon, MD, Co-managing director of SDG LLC; V. Strand, MD, MACR, FACP, Biopharmaceutical Consultant; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute. dbeaton@iwh.on.ca. 3. From the Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Clinical Epidemiology Program, and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ontario, Canada; Department of Epidemiology and Biostatistics, and Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia. 4. D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; B.J. Shea, PhD, Senior Scientist, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; L.J. Maxwell, PhD, Methodological Advisory to the Technical Advisory Group, OMERACT, University of Ottawa, and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; S. Grosskleg, BS, Secretariat, OMERACT, and University of Ottawa; C.O. Bingham III, MD, Professor of Medicine, Division of Rheumatology, Johns Hopkins University; P.G. Conaghan, MD, PhD, Director, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Deputy Director, NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Sorbonne Université, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research, and Head of Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama at Birmingham; L.S. Simon, MD, Co-managing director of SDG LLC; V. Strand, MD, MACR, FACP, Biopharmaceutical Consultant; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute.
Abstract
OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process used for core outcome measurement set selection to add rigor and transparency in decision making. This paper describes OMERACT's methodology for instrument selection. METHODS: We presented instrument selection processes, tools, and reporting templates at OMERACT 2018, introducing the concept of "3 pillars, 4 questions, 7 measurement properties, 1 answer." Truth, discrimination, and feasibility are the 3 original OMERACT pillars. Based on these, we developed 4 signaling questions. We introduced the Summary of Measurement Properties table that summarizes the 7 measurement properties: truth (domain match, construct validity), discrimination [test-retest reliability, longitudinal construct validity (responsiveness), clinical trial discrimination, thresholds of meaning], and feasibility. These properties address a set of standards which, when met, answer the one question: Is there enough evidence to support the use of this instrument in clinical research of the benefits and harms of treatments in the population and study setting described? The OMERACT Filter 2.1 was piloted on 2 instruments by the Psoriatic Arthritis Working Group. RESULTS: The methodology was reviewed in a full plenary session and facilitated breakout groups. Tools to facilitate retention of the process (i.e., "The OMERACT Way") were provided. The 2 instruments were presented, and the recommendation of the working group was endorsed in the first OMERACT Filter 2.1 Instrument Selection votes. CONCLUSION: Instrument selection using OMERACT Filter 2.1 is feasible and is now being implemented.
OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process used for core outcome measurement set selection to add rigor and transparency in decision making. This paper describes OMERACT's methodology for instrument selection. METHODS: We presented instrument selection processes, tools, and reporting templates at OMERACT 2018, introducing the concept of "3 pillars, 4 questions, 7 measurement properties, 1 answer." Truth, discrimination, and feasibility are the 3 original OMERACT pillars. Based on these, we developed 4 signaling questions. We introduced the Summary of Measurement Properties table that summarizes the 7 measurement properties: truth (domain match, construct validity), discrimination [test-retest reliability, longitudinal construct validity (responsiveness), clinical trial discrimination, thresholds of meaning], and feasibility. These properties address a set of standards which, when met, answer the one question: Is there enough evidence to support the use of this instrument in clinical research of the benefits and harms of treatments in the population and study setting described? The OMERACT Filter 2.1 was piloted on 2 instruments by the Psoriatic Arthritis Working Group. RESULTS: The methodology was reviewed in a full plenary session and facilitated breakout groups. Tools to facilitate retention of the process (i.e., "The OMERACT Way") were provided. The 2 instruments were presented, and the recommendation of the working group was endorsed in the first OMERACT Filter 2.1 Instrument Selection votes. CONCLUSION: Instrument selection using OMERACT Filter 2.1 is feasible and is now being implemented.
Entities:
Keywords:
HEALTH STATUS INDICATOR; OMERACT; OUTCOME ASSESSMENT; OUTCOME MEASURES; RELIABILITY AND VALIDITY; REPRODUCIBILITY OF RESULTS
Authors: Tina Esfandiary; Jin Kyun Park; Helene Alexanderson; Malin Regardt; Merrilee Needham; Ingrid de Groot; Catherine Sarver; Ingrid E Lundberg; Marianne de Visser; Yeong Wook Song; Dana DiRenzo; Clifton O Bingham; Lisa Christopher-Stine; Christopher A Mecoli Journal: Semin Arthritis Rheum Date: 2020-06-17 Impact factor: 5.532
Authors: David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna Journal: Semin Arthritis Rheum Date: 2021-08-20 Impact factor: 5.431
Authors: Alison H Kohn; Afsaneh Alavi; April W Armstrong; Folawiyo Babalola; Amit Garg; Alice B Gottlieb; Lesley Grilli; Gregor Borut Ernst Jemec; John Latella; Kendall Marcus; Joseph F Merola; Alex G Ortega-Loayza; Daniel M Siegel; Vibeke Strand; Jerry K L Tan; Lourdes M Perez-Chada Journal: Dermatology Date: 2021-09-17 Impact factor: 5.197
Authors: Shelley Vanderhout; Stuart Nicholls; Zarah Monfaredi; Claudia Hampel; Lynn Ashdown; Maxime Bilodeau; Susan Rich; Beverley Shea; Dean Fergusson Journal: Res Involv Engagem Date: 2022-06-07
Authors: Kaitlin A Quinn; Sara Monti; Robin Christensen; David Jayne; Carol A Langford; Georgia E Lanier; Alfred Mahr; Christian Pagnoux; Beverley Shea; Maria Bjork Viðarsdóttir; Gunnar Tomasson; Peter A Merkel Journal: Semin Arthritis Rheum Date: 2022-04-28 Impact factor: 5.431
Authors: Ying Ying Leung; Ana-Maria Orbai; Alexis Ogdie; Pil Hojgaard; Richard Holland; Niti Goel; Jeffrey Chau; Laura C Coates; Vibeke Strand; Dafna D Gladman; Philip J Mease; Robin Christensen; William Tillett Journal: J Rheumatol Date: 2020-02-01 Impact factor: 5.346
Authors: Ying Ying Leung; William Tillett; Pil Hojgaard; Ana-Maria Orbai; Richard Holland; Ashish J Mathew; Niti Goel; Jeffrey Chau; Christine A Lindsay; Alexis Ogdie; Laura C Coates; Robin Christensen; Philip J Mease; Vibeke Strand; Dafna D Gladman Journal: J Rheumatol Date: 2021-04-15 Impact factor: 5.346
Authors: Philippe Bérubé-Mercier; Diane Tapp; Marie-Ève Cimon; Tiffany Li; Susanna B Park; Éve Bouhêlier; Kaitlin McGarragle; Lye-Ann Robichaud; Jennifer S Gewandter; Maxime Bouchard; Lynn R Gauthier Journal: BMJ Open Date: 2022-04-06 Impact factor: 2.692
Authors: Lindsay Tetreault; Philip Garwood; Aref-Ali Gharooni; Alvaro Yanez Touzet; Laura Nanna-Lohkamp; Allan Martin; Jefferson Wilson; James S Harrop; James Guest; Brian K Kwon; James Milligan; Alberto Martinez Arizala; K Daniel Riew; Michael G Fehlings; Mark R N Kotter; Sukhvinder Kalsi-Ryan; Benjamin M Davies Journal: Global Spine J Date: 2021-12-31